Key points
Of all the conditions where low-dose naltrexone (LDN) is discussed, fibromyalgia has the strongest evidence base — including a defining randomized placebo-controlled crossover trial.
| Where | How it helps | What human studies showed |
|---|---|---|
| Fibromyalgia pain | may reduce pain — in some patients; 4.5 mg at bedtime | crossover RCT, 31 women: pain fell by 28.8% on LDN versus 18.0% on placebo, p=0.016 (Younger 2013) |
| Neuroinflammation in the CNS | suppresses microglial activation via TLR4 | 8 people with fibromyalgia, 8 weeks of treatment: IL-6 and TNF-α fell in the blood (Parkitny 2017) |
| Chronic pain in practice | subjective relief | retrospective cohort from one practice, 93 patients (fibromyalgia — 27): relief in 53.8% (Aalto 2025) |
| Severe fibromyalgia, long-term use | improvement on an individualized dose | case report of one patient over 2 years (Moser 2025) |
How it helps
The defining trial: Younger 2013
A randomized, double-blind, placebo-controlled, crossover trial (Younger J, et al. Arthritis Rheum 2013;65:529–538, PMID 23359310) enrolled 31 women with fibromyalgia: each participant received both LDN 4.5 mg and placebo during different phases of the study.
Result: baseline pain reduction of 28.8% on LDN versus 18.0% on placebo (p=0.016) — a statistically significant difference, a measurable effect in a subset of patients.
Mechanism: microglia and neuroinflammation
Unlike autoimmune conditions, the key mechanism in fibromyalgia is less about Th17/Treg balance and more about suppressing microglial activation in the CNS. Low-dose naltrexone acts as a TLR4 (Toll-like receptor 4) antagonist on microglia, reducing production of pro-inflammatory cytokines; in people with fibromyalgia on LDN, blood IL-6 and TNF-α fell (Parkitny L, Younger J. Biomedicines 2017;5:16. PMID 28536359).
Chronic microglial activation is linked to central sensitization — a state where the CNS amplifies pain signals independent of peripheral tissue damage. This is a key distinction of fibromyalgia from inflammatory/structural pain syndromes, and it is why LDN's anti-inflammatory effect at the CNS level, rather than the periphery, is relevant here.
Newer observations from 2025
A single-patient case report with 2-year follow-up (Moser U. Cureus 2025. PMID 40491623) described improvement on individualized LDN dosing. A retrospective cohort from one pain-medicine practice (Aalto H, et al. J Pain Res 2025. PMID 41399763; fibromyalgia was the largest subgroup, 27 of 93 patients) reported subjective symptom relief in 53.8% of patients.
How to take it
▸ Start at 1.5 mg at bedtime for 2–4 weeks.
▸ +1.5 mg every 1–2 weeks as tolerated, up to a target dose of 4.5 mg/day (the dose used in the defining RCT).
▸ Target dose — 4.5 mg: there is no need to go above it "for a stronger effect" — no benefit above 4.5 mg has been shown.
▸ Form — compounded; the standard 50 mg tablet does not provide the required dose.
▸ Assess effect — no earlier than 6–8 weeks at the target dose. If there is no effect after 8–12 weeks at 4.5 mg, discuss discontinuation and other strategies with a physician.
▸ First 1–2 weeks' side effects — vivid dreams, difficulty falling asleep — usually resolve by day 10–14.
▸ Alongside core care — in the Younger trial, LDN supplemented rather than replaced standard care (sleep, physical activity, stress management).
Who should see a doctor first
▸ A confirmed fibromyalgia diagnosis (not self-diagnosis by symptoms).
▸ Insufficient response to standard first-line therapy (physical activity, cognitive behavioral therapy, and when indicated, duloxetine/pregabalin/milnacipran).
▸ Comorbid Hashimoto's or another autoimmune condition — discuss LDN as a potentially shared strategy.
▸ Discuss any LDN plan with your treating physician before starting — contraindications (concurrent opioid use, pregnancy) must be excluded.
Bottom line
Fibromyalgia is the only LDN indication with a defining crossover RCT (Younger 2013): 4.5 mg dose, 28.8% pain reduction versus 18.0% on placebo. The mechanism is suppression of microglial activation and pro-inflammatory cytokines in the CNS.
I assess indications for LDN in fibromyalgia and coordinate titration and monitoring together with specialists for any comorbid conditions.
Related article: Low-dose naltrexone (LDN) in Hashimoto thyroiditis — same drug, overlapping mechanism, frequently co-occurring conditions.
Sources
▸ Younger J, Noor N, McCue R, Mackey S. Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial. Arthritis Rheum 2013;65:529–538. PMID 23359310 — evidence level 1b (RCT).
▸ Bruun KD, et al. Naltrexone 6 mg once daily versus placebo in women with fibromyalgia: a randomised, double-blind, placebo-controlled trial. Lancet Rheumatol 2024;6(1):e31-39. PMID 38258677 — evidence level 1b (RCT, n=99); pain outcome not different from placebo (p=0.27).
▸ Parkitny L, Younger J. Reduced pro-inflammatory cytokines after eight weeks of low-dose naltrexone for fibromyalgia. Biomedicines 2017;5:16. PMID 28536359 — mechanistic data (n=8, uncontrolled).
▸ Moser U. Low-dose naltrexone for severe fibromyalgia syndrome: a report of a case with two-year follow-up. Cureus 2025. PMID 40491623 — evidence level 4 (case report, n=1).
▸ Aalto H, Paul S, McEwen V. Real-world effectiveness and tolerability of low dose naltrexone to treat chronic pain: a retrospective cohort study of one pain physician's practice. J Pain Res 2025. PMID 41399763 — evidence level 3 (retrospective cohort, n=93; fibromyalgia subgroup n=27).
Further reading: LDN Research Trust.
Source: Low-Dose Naltrexone (LDN) for Fibromyalgia: Dosing, Evidence, What to Expect — universum.earth. md_pereligyn — Перелыгин Владимир Игоревич.
